Tweet
J Med Virol
. 2025 Apr;97(4):e70326.
doi: 10.1002/jmv.70326. Broad Mucosal and Systemic Immunity in Mice Induced by Intranasal Booster With a Novel Recombinant Adenoviral Based Vaccine Protects Against Divergent Influenza A Virus
Jia Li 1 , Tangqi Wang 1 2 , Xiaojuan Guo 2 , Yujie Jiang 1 , Liye Jin 3 , Qiaohong Chu 2 , Xuchang Shan 3 , Lingfang Zhang 4 , Ruiwen Han 1 2 , Chengcheng Zhai 2 , Donghong Wang 2 , Yao Deng 2 , Baoying Huang 2 , Zhuozhuang Lu 2 , Wenjie Tan 1 2
Affiliations
The development of broad-spectrum universal influenza vaccines and optimization of vaccination strategies to address the threats posed by pandemics and emerging influenza viruses are critical for public health. In this study, an adenovirus type 5 vector-based influenza vaccine carrying the hemagglutinin (HA) stem of H1, HA stem of H3, and neuraminidase (NA) of N1 from the influenza virus was constructed. Immune responses were evaluated in mice using various vaccination strategies: prime-only (intramuscular [IM] or intranasal [IN]) and prime-boost (IM + IN). Compared with the prime-only strategy, the prime-boost strategy significantly enhanced the systemic immune response, inducing higher levels of antigen-specific IgG, mucosal IgA, and T cell immunity in the spleen and lungs. Furthermore, the IN boosting strategy provided complete protection in mice challenged with the H1N1-PR8, rgH3N2-X31, and rgH5N1-Vietnam viruses, significantly reducing viral loads in the lungs and alleviating lung tissue pathologies. In conclusion, this study elucidates potential avenues for the development and application of universal influenza vaccines using customized mucosal boosting strategies.
Keywords: adenovirus vector‐based influenza vaccine; intranasal booster; mucosal immunity; systemic immunity; universal influenza vaccine.
. 2025 Apr;97(4):e70326.
doi: 10.1002/jmv.70326. Broad Mucosal and Systemic Immunity in Mice Induced by Intranasal Booster With a Novel Recombinant Adenoviral Based Vaccine Protects Against Divergent Influenza A Virus
Jia Li 1 , Tangqi Wang 1 2 , Xiaojuan Guo 2 , Yujie Jiang 1 , Liye Jin 3 , Qiaohong Chu 2 , Xuchang Shan 3 , Lingfang Zhang 4 , Ruiwen Han 1 2 , Chengcheng Zhai 2 , Donghong Wang 2 , Yao Deng 2 , Baoying Huang 2 , Zhuozhuang Lu 2 , Wenjie Tan 1 2
Affiliations
- PMID: 40145257
- DOI: 10.1002/jmv.70326
The development of broad-spectrum universal influenza vaccines and optimization of vaccination strategies to address the threats posed by pandemics and emerging influenza viruses are critical for public health. In this study, an adenovirus type 5 vector-based influenza vaccine carrying the hemagglutinin (HA) stem of H1, HA stem of H3, and neuraminidase (NA) of N1 from the influenza virus was constructed. Immune responses were evaluated in mice using various vaccination strategies: prime-only (intramuscular [IM] or intranasal [IN]) and prime-boost (IM + IN). Compared with the prime-only strategy, the prime-boost strategy significantly enhanced the systemic immune response, inducing higher levels of antigen-specific IgG, mucosal IgA, and T cell immunity in the spleen and lungs. Furthermore, the IN boosting strategy provided complete protection in mice challenged with the H1N1-PR8, rgH3N2-X31, and rgH5N1-Vietnam viruses, significantly reducing viral loads in the lungs and alleviating lung tissue pathologies. In conclusion, this study elucidates potential avenues for the development and application of universal influenza vaccines using customized mucosal boosting strategies.
Keywords: adenovirus vector‐based influenza vaccine; intranasal booster; mucosal immunity; systemic immunity; universal influenza vaccine.